How to Help Your Patients Find the Adenovirus Vaccine: A Provider's Guide for 2026

The Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is one of the DoD's most operationally important biologics—yet it is often misunderstood by providers who work primarily in civilian or mixed-setting environments, and even by some military providers who may not have directly managed adenovirus vaccine administration during their training.

This guide is designed for military medical officers, flight surgeons, preventive medicine specialists, and immunization nurses who work with recruits and other at-risk military personnel. We cover who is eligible, how to screen for contraindications, how to counsel recruits on the post-vaccination period, and what to do when a recruit cannot receive the vaccine.

Who Should Receive the Adenovirus Vaccine?

The vaccine is FDA-approved for military populations aged 17 through 50. The DoD recommends it specifically for:

All military recruits entering basic training at one of the nine authorized training installations (Army, Navy, Marine Corps, Air Force, Space Force, Coast Guard)

Military academy cadets (Naval Academy, Coast Guard Academy, Air Force Academy, and others) entering intensive training environments

Other active duty personnel at high risk for adenovirus infection (e.g., those entering crowded, high-density living environments for the first time)

Vaccination is not recommended for personnel who have previously received the vaccine and have likely developed immunity—though serologic immunity testing is not routinely performed before vaccination in the basic training setting.

Pre-Vaccination Screening: What Providers Must Check

Before administering the vaccine, providers or immunization nurses must assess each recruit for the following contraindications and precautions. All three absolute contraindications require withholding the vaccine:

Pregnancy (Absolute Contraindication): Ask all female recruits of childbearing potential if they are pregnant or may be pregnant. The vaccine is absolutely contraindicated in pregnancy. Counsel women to use effective contraception for 6 weeks post-vaccination. Enroll any woman inadvertently vaccinated during pregnancy in the Adenovirus Pregnancy Registry (1-866-790-4549).

Severe Allergy (Absolute Contraindication): Ask about prior severe allergic reactions (anaphylaxis) to any vaccine component. The vaccine contains human albumin (<0.3 mg/tablet), anhydrous lactose, microcrystalline cellulose, polacrilin potassium, and magnesium stearate.

Inability to Swallow Tablets Whole (Absolute Contraindication): Ask recruits if they are able to swallow large tablets whole without chewing or crushing. Demonstrate the tablet size if needed. Chewing releases the live virus in the oropharynx.

Precautions (defer vaccination until resolved): active vomiting or diarrhea (defer until resolved), current moderate-to-severe acute illness (defer until recovery), immunocompromised status (consult commander and Medical Director for risk-benefit assessment).

Administration: Step-by-Step Protocol

The Adenovirus Vaccine is administered as follows:

Verify cold chain integrity: Confirm the vaccine has been stored at appropriate temperature throughout the supply chain. Cold chain deviations should be reported.

Prepare the dose: The single-dose package contains two enteric-coated tablets—one Type 4 (no dye) and one Type 7 (contains FD&C Yellow #6).

Instruct the recruit: Both tablets are taken together, swallowed whole with water. Do not crush, chew, or break the tablets. Confirm the recruit can swallow the tablets before administration.

Observe after administration: Monitor for immediate adverse reactions. Have epinephrine available in the event of anaphylaxis.

Document in the recruit's immunization record and in AHLTA/MHS Genesis as appropriate.

Post-Vaccination Counseling: The Critical 28-Day Window

Post-vaccination counseling is essential because this is a live virus vaccine with documented fecal shedding. Providers must communicate clearly that:

The live vaccine virus is shed in stool starting approximately day 7 and continuing for up to 28 days post-vaccination

Frequent and thorough handwashing (especially after bowel movements and before eating) is required throughout the shedding period

During home leave or weekend passes, close contact with pregnant family members, children under 7, and immunocompromised household members should be avoided

Female recruits must use contraception for 6 weeks post-vaccination. Any suspected pregnancy within 6 weeks of vaccination requires immediate reporting to the Adenovirus Pregnancy Registry.

Adverse Event Reporting and the VAERS Database

Adverse events following adenovirus vaccination should be reported to VAERS (Vaccine Adverse Event Reporting System). VAERS data from October 2011 through July 2018 identified 100 reports, of which 39% were classified as serious. The most frequently reported serious adverse events were Guillain-Barré syndrome (n=12) and anaphylaxis (n=8). Importantly, no unexpected or concerning pattern of adverse events was identified compared to other vaccines administered in the same military population.

Additionally, all cases of possible vaccine-associated Guillain-Barré syndrome, anaphylaxis, or pregnancy exposure should be reported through appropriate military and civilian channels (VAERS, DoD Vaccine Clinical Call Center: 1-866-210-6469, 24-hour toll-free).

For providers working with patients who need help accessing other specialty medications at civilian pharmacies, medfinder for providers can locate in-stock pharmacies on your patients' behalf, reducing care gaps.

For the provider guide on shortage management strategies, see: Adenovirus Vaccine Shortage: What Providers and Prescribers Need to Know in 2026.